Table 1 Minimum inhibitory concentrations (MICs) of CBD (μg mL−1).
(a) Gram-positive (resistant strains in bold) | |||||||
|---|---|---|---|---|---|---|---|
Species | Strain | Vancomycin | Daptomycin | Trimethoprim | Mupirocin | Clindamycin | CBD |
Staphylococcus aureus | ATCC 25923 MSSA | 1–2 | 1–2 | 2–4 | 0.25–0.5 | 0.06–0.25 | 1–2 |
Staphylococcus aureus | ATCC 43300 MRSA | 0.5–1 | 0.5–1 | 2 | 0.125–0.5 | >64 | 1–2 |
Staphylococcus aureus | NRS-1 MRSA VISA | 2–4 | 4–8 | 2–4 | 0.125–0.5 | 64 | 1–4 |
Staphylococcus aureus | VRS1 VRSA | >64 | 1–4 | >64 | 32–64 | >64 | 1–2 |
Staphylococcus epidermidis | ATCC 12228 | 1–2 | 1–8 | 1–4 | 0.25–0.5 | 0.06–0.25 | 1–2 |
Staphylococcus epidermidis | NRS-60 VISE | 2–4 | 1–4 | >64 | 0.125–0.5 | 0.06–0.125 | 4–8 |
Streptococcus pneumoniae | ATCC 33400 | 0.5–1 | 1–4 | 0.5–2 | 0.25–0.5 | 0.06–2 | 1–2 |
Streptococcus pneumoniae | ATCC 700677 MDR | 1 | 1–4 | 1–2 | 0.25–0.5 | >64 | 1–4 |
Streptococcus pyogenes | ATCC 12344 | 0.25–0.5 | 0.125–0.25 | 2–4 | ≤0.03 | 0.125–0.25 | 1 |
Enterococcus faecium | ATCC 35667 | 0.25–0.5 | 4–8 | ≤0.03–0.06 | 1 | ≤0.03–0.06 | 0.5–1 |
Enterococcus faecium | ATCC 700221 | >64 | 8 | 16 | 2 | >64 | 1 |
Enterococcus faecalis | ATCC 29212 | 1–2 | 4–8 | 0.25–0.5 | 64 | 16–32 | 2 |
Enterococcus faecalis | clinical isolate | >64 | 8 | >64 | >64 | >64 | 2–4 |
Vancomycin | Levofloxacin | Meropenem | Gentamicin | CBD | |||
Enterococcus faecalis | MMX 486 VRE | >16 | >32 | 4 | >32 | 1 | |
Enterococcus faecium | ATCC 19434 | 0.25 | 4 | 8 | 4 | 0.5 | |
Enterococcus faecium | MMX 485 VRE | >32 | 1 | >32 | >32 | 1 | |
Anaerobic growth conditions | |||||||
Vancomycin | Erythromycin | Tetracycline | Mupirocin | Clindamycin | CBD | ||
Staphylococcus aureus | ATCC 43300 MRSA | 0.5–1 | >32 | 0.06–0.25 | 0.03–0.06 | >32 | 1–2 |
Cutibacterium acnes | ATCC 6919 | 0.25 | 0.125–0.25 | 0.125–0.5 | >32 | 0.125 | 1–2 |
Clostridioides difficile | M7404 human ribotype 027 | 2–4 | |||||
(b) Gram-negative | ||||||
|---|---|---|---|---|---|---|
Species | Strain | Colistin | Trimethoprim | Mupirocin | Clindamycin | CBD |
Escherichia coli | ATCC 25922 | 0.06–0.125 | 0.5–2 | >64 | >64 | >64 |
Klebsiella pneumoniae | ATCC 700603, ESBL | 0.125–1 | 8–16 | >64 | >64 | >64 |
Pseudomonas aeruginosa | ATCC 27853 | 0.25–1 | >64 | >64 | >64 | >64 |
Vancomycin | Levofloxacin | Meropenem | Gentamicin | CBD | ||
Acinetobacter baumannii | ATCC 19606 | >32 | 0.25 | 0.5 | 8 | >64 |
Serratia marcescens | MMX 6462 | >32 | 0.06 | 4 | 1 | >64 |
Stenotrophomonas maltophila | MMX 4746 | >32 | 0.5 | 8 | 0.5 | >64 |
Burkholderia cepacia | MMX 547 | >32 | 1 | 1 | >32 | >64 |
Proteus mirabilis | MMX 6442 | >32 | 0.03 | ≤0.03 | 0.25 | >64 |
Salmonella typhimurium | ATCC 35987 | >32 | 0.03 | ≤0.03 | 0.25 | >64 |
Shigella dysenteriaev | ATCC 29026 | >32 | 0.03 | ≤0.03 | 0.5 | >64 |
Haemophilus influenzae | ATCC 49247 | >32 | 0.015 | 0.5 | 1 | >64 |
Moraxella catarrhalis | MMX 3782 | 32 | 0.03 | ≤0.03 | 0.25 | 1 |
Neisseria gonorrhoeae | ATCC 49226 | 8 | 0.002 | ≤0.03 | 4 | 1 |
Neisseria meningitidis | ATCC 13090 | >32 | 0.004 | ≤0.03 | 8 | 0.25 |
Legionella pneumophila | MMX 7515 | 0.12 | 0.5 | 0.25 | 1 | 1 |
